Abstract
Bristol-Myers Squibb will release first-quarter results on April 30, 2026 Pre-Market, with consensus pointing to stable revenue and modest earnings pressure as investors weigh destocking, policy headwinds, and near-term pipeline catalysts.Market Forecast
For the current quarter, forecasts point to revenue of 10.85 billion US dollars, up 1.46% year over year, adjusted EPS of 1.41, down 5.57% year over year, and EBIT of 3.68 billion US dollars, up 0.54% year over year. Forecast data for gross margin and net profit margin is not available.The main portfolio is projected to be anchored by cardiovascular and immuno-oncology franchises, with last quarter’s mix led by Eliquis and Opdivo that together represented roughly half of sales, while oncology trends may be uneven due to inventory and policy dynamics. Camzyos, Breyanzi, and Reblozyl comprise the most promising growth cluster in the near term based on clinical progress and a growing commercial base, with last quarter sales of 0.35 billion, 0.39 billion, and 0.67 billion US dollars respectively; year-over-year comparisons by product were not disclosed in the quarterly breakdown.
Last Quarter Review
In the prior quarter, Bristol-Myers Squibb delivered revenue of 12.50 billion US dollars (+1.30% year over year), a gross profit margin of 71.95%, GAAP net profit attributable to the parent company of 1.09 billion US dollars, a net profit margin of 8.69%, and adjusted EPS of 1.26 (−24.55% year over year).A key highlight was the upside versus expectations: revenue and EPS exceeded consensus, supported by solid execution in core brands despite known headwinds from loss-of-exclusivity dynamics. By product, Eliquis generated 3.45 billion US dollars, Opdivo 2.69 billion US dollars, Orencia 1.01 billion US dollars, Yervoy 0.81 billion US dollars, and the newer-growth portfolio added breadth with Reblozyl at 0.67 billion US dollars, Breyanzi at 0.39 billion US dollars, and Camzyos at 0.35 billion US dollars, underscoring a diversified contribution across therapeutic areas; year-over-year growth rates by product were not provided in the quarterly mix.
Current Quarter Outlook (with major analytical insights)
Core portfolio performance and earnings sensitivity
The near-term earnings profile centers on stability in the cardiovascular and immuno-oncology pillars. Eliquis and Opdivo comprised approximately 49% of last quarter’s revenue, providing a substantial base for the quarter now being reported. Forecasts imply total revenue of 10.85 billion US dollars and adjusted EPS of 1.41, reflecting incremental year-over-year sales growth with modest EPS pressure, consistent with a quarter where inventory and policy dynamics can mask underlying prescription trends. Within this backdrop, the company’s 71.95% gross margin in the prior quarter sets a high baseline for profitability, but mix and stock movements can introduce volatility in quarterly margins.Oncology is expected to face uneven quarterly compares as suggested by recent commentary highlighting destocking patterns and generic sequencing that complicate year-over-year visibility. That does not necessarily indicate demand weakness for key assets such as Opdivo; rather, it implies that reported figures may lag underlying utilization in a given quarter. This is why consensus embeds a slight negative year-over-year change for EPS despite a revenue increase, as margin factors and spending on launches and late-stage development can dilute near-term earnings conversion. The EBIT forecast of 3.68 billion US dollars (+0.54% year over year) captures this resilient yet constrained profitability profile for the period.
The net effect is that even small deviations in channel inventory, rebate accruals, or product mix can lead to outsized movement in quarterly EPS. Investors should expect management to contextualize these factors on the call, linking any below-the-line items and phasing effects to full-year cadence. Importantly, last quarter’s positive surprises relative to estimates demonstrate that the company can execute through these swings; the question for this quarter is how clean the revenue quality proves to be and whether operating expense timing aligns with the top line.
Growth platforms and early-launch momentum
Newer assets continue to expand their footprint and are likely to be key talking points this quarter. Camzyos has advanced clinically, with a recent Phase 3 study in adolescents with symptomatic obstructive hypertrophic cardiomyopathy meeting its primary endpoint, supporting a potential label expansion path and, over time, a larger addressable population. While quarter-to-quarter revenue may remain small relative to the company’s scale, Camzyos’s 0.35 billion US dollars contribution last quarter represents a meaningful addition given its early stage of commercialization, and positive clinical updates tend to strengthen the asset’s adoption trajectory.Reblozyl’s 0.67 billion US dollars last quarter underscores its role as a durable hematology driver. Continued adoption across approved indications and further clinical progress can sustain its upward slope, though policy headwinds and access dynamics may influence near-term run-rates. Breyanzi’s 0.39 billion US dollars contribution demonstrates that cell therapy is increasingly a commercial pillar for the company. Manufacturing reliability, broadened site onboarding, and potential label enhancements are the levers that can improve patient access and treatment volumes, thereby deepening revenue over time. Across these three assets, the theme for the quarter is momentum sustainability rather than absolute scale, given their still-ramping status.
Partnership updates also add incremental confidence to the growth arc. Recent collaborations around RNA therapeutics and diagnostics, alongside development milestones reported by partners, indicate continued external validation and potential pipeline breadth. These items rarely move quarterly revenue in the short run, but they inform medium-term optionality. For the present quarter, investors will be most interested in whether reported sales confirm the sequential ramp implied by last quarter’s base and whether management comments guide toward steadier full-year trajectories for these growth platforms.
Key stock price drivers this quarter
Three factors are likely to exert the largest influence on the share price in connection with the print. The first is revenue quality and inventory dynamics. Commentary has emphasized that modeling this quarter is complicated by destocking and phasing effects. If the company can demonstrate that any volume softness is predominantly inventory-related, investors may look through near-term variability. Conversely, indications of demand deceleration, particularly in oncology, could pressure the multiple even if headline revenue meets estimates.The second is the mix of mature and LOE-affected products versus growth assets. Revlimid erosion and policy headwinds can weigh on margins and obscure progress from assets such as Reblozyl, Camzyos, and Breyanzi. A clearer articulation of how these growth brands are pacing relative to internal plans—and how expenses are being calibrated to support them—would help investors judge whether the −5.57% year-over-year EPS forecast is a trough-like point or a steady-state trend. The EBIT trajectory (+0.54% year over year) suggests underlying operational resilience, but the magnitude of launch spending and any incremental investments can swing near-term EPS.
The third factor is pipeline and late-stage readouts. Preview notes emphasize that investor focus this quarter will be on late-stage data for key candidates—particularly the timing and quality of updates for milvexian and other prioritized programs. This matters because the pathway to a sustained return to growth hinges on translating pipeline progress into commercial revenue within the planning horizon. Positive clarity on timelines and regulatory interactions can counterbalance near-term quarterly noise and support valuation, while ambiguity or slippage could reinforce a wait-and-see posture among generalists.
Analyst Opinions
The majority view among institutions is neutral, with several firms maintaining Hold or equivalent ratings and price targets clustered around the high-50s to low-60s. The consensus emerging from these assessments is that the quarter is likely to land broadly in line with expectations, with near-term variability driven more by inventory and policy mechanics than by fundamental demand shifts in the flagship brands.RBC Capital Markets reiterates a sector perform stance and projects first-quarter revenue of 10.75 billion US dollars and non-GAAP EPS of 1.42, noting that the period is difficult to model given destocking patterns, tough year-over-year comparisons, policy impacts, and generic phasing. The message is that the print should be relatively uneventful on the headline numbers, but the call will be the focal point for insights on late-stage programs—including milvexian and other catalysts—that can delineate the company’s return-to-growth timing. This framing supports the neutral stance: fundamental stability is intact, but greater visibility on growth inflection is required to shift views.
Bernstein maintains a Hold rating with a mid-to-high 50s price target, balancing solid near-term execution with limited long-term visibility. Their perspective fits the neutral majority: core assets are executing, but multiple-compressing forces—policy, LOE, and the time gap to pipeline scale—argue for patience. William Blair also retains a neutral posture, pointing to supportive clinical data in the CELMoD platform and other emerging programs while flagging long-term execution risks and launch pacing as key swing variables. Berenberg keeps a Hold with a 60 US dollars target, similarly seeking confirmation that new launches can offset LOE headwinds within the expected time frame. Cantor Fitzgerald’s Neutral with a mid-50s target complements this cluster of views, focusing attention on incremental evidence that recently launched assets can achieve durable, predictable growth trajectories.
Across these neutral assessments, the common analytical threads are clear. First, the revenue outlook for the current quarter is not the primary debate; consensus sits near the company’s modeled range at 10.85 billion US dollars with a modest 1.46% year-over-year increase, and non-GAAP EPS around 1.41 is consistent with margin and expense mix. Second, oncology noise related to inventory movements and policy remains a near-term modeling complication, which is why analysts emphasize reading through quarterly fluctuations to underlying prescriptions. Third, the arrival cadence of pipeline catalysts is seen as the gating factor for a sustained re-rating: clarity on late-stage data, regulatory milestones, and label expansions—especially for assets that can scale into multi-hundred-million or billion-dollar run-rates—will influence whether the neutral camp migrates toward a more constructive stance in the coming quarters.
In total, the neutral majority expects an in-line quarter on the headline metrics, with the call’s qualitative updates on inventory normalization, expense pacing, and the timing of pivotal pipeline events serving as the principal determinants of post-print sentiment. If management can demonstrate that growth platforms are tracking to plan and that anticipated catalysts remain on schedule, analysts indicate that the current valuation framework could accommodate a steadier path back to earnings growth despite ongoing LOE and policy pressures. Conversely, any signs that oncology softness is demand-related rather than inventory-related, or that late-stage timelines are slipping, would likely keep the balance of views anchored at Hold as investors await stronger evidence of acceleration.
Comments